This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab.
Immunotherapy has shown efficacy in lung cancer, with several drugs already approved for patients with non–small-cell lung cancer (anti–PD-1 agent nivolumab, anti–PD-L1 agents pembrolizumab and atezolizumab).
In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses immunotherapies in the small-cell lung cancer (SCLC) setting.
Kalemkerian reviews the results of several trials in SCLC, including nivolumab monotherapy or in combination with the CTLA-4 blocker ipilimumab, and pembrolizumab.
Related Content:Lung Cancer